Nonalcoholic fatty liver disease (NAFLD) is an increasingly common condition that is
believed to affect> 25% of adults worldwide. Unless specific testing is done to identify …

Nonalcoholic fatty liver disease (NAFLD) spans steatosis through nonalcoholic
steatohepatis, cirrhosis, and hepatocellular carcinoma (HCC) associated with striking …

Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) are both
manifestations of end-organ damage of the metabolic syndrome. Through multiple …

Nonalcoholic fatty liver disease (NAFLD) is a systemic disorder with a complex multifactorial
pathogenesis and heterogenous clinical manifestations. NAFLD, once believed to be an …

The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing rapidly worldwide
as the obese and diabetic populations increase, and it has been estimated to be 20–30% in …

Background & Aims Cardiovascular disease remains the leading cause of death in patients
with nonalcoholic fatty liver disease (NAFLD). Studies examining the association of coronary …

Background Several steatosis biomarkers are available with limited independent validation.
Aim To determine diagnostic value and limitations of several steatosis biomarkers using liver …

Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease, and is
strongly associated with the metabolic syndrome. In the last decade, it has become apparent …

Transmembrane 6 superfamily member 2 (TM6SF2) is located on chromosome 19 (19p12)
and encodes for a protein of undetermined function. Genetic studies have reported the …

Background & Aims Aerobic exercise reduces liver fat and visceral adipose tissue (VAT).
However, there is limited data from randomized trials to inform exercise programming …